Follow The Filings

HROW Harrow Health Inc.

Health Care, filed as HARROW HEALTH INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2, sold by 1

  • 2 Owners
  • Max 9.2%
  • $136M
  • 1 new 1 reduce

In 2026 Q2 Ron Baron opened a position in Harrow Health, while James Silverman trimmed.

Who owns this now

Largest portfolio weights among holders, up to 9.2% (James Silverman, Opaleye Management). Not free-float ownership.

  1. James Silverman Reduce 9.2%
  2. Ron Baron New 0.05%

Who owns HROW

Sorted by value, long equity only, as of 2026 Q2.

History
James Silverman, Opaleye Management 9.2%, was 13.2% Reduce −15.3% 2,400,000 $102M History
Ron Baron, Bamco Inc. (Baron Capital) 0.05% New 0.05% 809,350 $34M History

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by HROW's executives, directors and 10% owners in the last 12 months, from their Form 4s

All HROW insider trades
  • $469K bought by 4 insiders
  • $9.6M sold by 2 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. Amir Shojaei Chief Scientific Officer
    Sale
    $450K 11,250 shares at $40.00 100% of stake
    Traded Aug 14 Filed Aug 17
  2. Adrienne L Graves Director
    Buy
    $31K 1,000 shares at $31.07 New stake
    Traded May 18 Filed May 19
  3. Lauren P Silvernail Director
    Buy
    $31K 1,000 shares at $31.00 New stake
    Traded May 18 Filed May 19
  4. Mark L Baum CEO
    Buy
    $302K 10,000 shares at $30.20 +0.3% to stake
    Traded May 14 Filed May 15
  5. Andrew R. Boll CFO
    Buy
    $105K 3,500 shares at $29.90 +0.4% to stake
    Traded May 14 Filed May 15
  6. Opaleye Management Inc. 10% owner
    Sale
    $7.8M 198,572 shares at $39.51 77% of stake
    Traded Mar 3–4 Filed Mar 5
  7. Opaleye Management Inc. 10% owner
    Sale
    $271K 5,000 shares at $54.18 7.1% of stake
    Traded Feb 27 Filed Mar 3
  8. Opaleye Management Inc. 10% owner
    Sale
    $1.1M 20,000 shares at $53.35 22% of stake
    Traded Jan 6 Filed Jan 8

Also filed in the last 12 months, not counted as buying or selling: 3 option exercises and 2 share withholdings for taxes.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 1.01,2.01,7.01,9.01
8-K 5.02,9.01
8-K 2.02,7.01,9.01
10-Q
8-K 1.01,7.01,9.01
SCHEDULE 13G/A —
8-K 5.07
8-K 7.01,9.01
SCHEDULE 13G/A —
8-K 2.02,7.01,9.01
10-Q
DEF 14A
DEFA14A
SCHEDULE 13G/A —
8-K 1.01,2.03,8.01,9.01
8-K 8.01,9.01
8-K 8.01,9.01
SCHEDULE 13G —
8-K 7.01,9.01
8-K 2.02,7.01,9.01
10-K
8-K 2.02,5.02,9.01
8-K 2.01,3.02,8.01,9.01
8-K 2.02,7.01,9.01
10-Q

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $130.19M $199.61M $272.3M
Gross profit $90.55M $150.37M $204.37M
Gross margin * 69.6% 75.3% 75.1%
Net income -$24.41M -$17.48M -$5.14M
Net margin * -18.7% -8.8% -1.9%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $139.48M $189.65M $211.75M
Total non-current assets * $172.68M $199.32M $187.73M
Total assets $312.16M $388.97M $399.48M
Total current liabilities $49.34M $91.34M $96.3M
Total non-current liabilities * $192.41M $228.33M $251.09M
Total equity $70.77M $69.65M $52.45M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $3.84M -$22.2M $43.86M
Cash from investing -$152.55M -$33.16M -$5.46M
Cash from financing $126.53M $28.53M -$12.72M
Net change in cash -$22.18M -$26.84M $25.68M

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.